查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456967

全球整容手術市場 - 2024 年至 2029 年預測

Global Cosmetic Surgery Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 136 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

整容手術市場預計將從2022年的482.4億美元成長到2029年的896.71億美元，複合年成長率為9.26%。

整容手術是一種利用手術和非手術方法來改善外觀的醫療手術。整容手術，也稱為整容手術，是整形手術的一部分，旨在透過外科手術和醫療程序來改善一個人的外表。整容手術是選擇性的，重點是改善美觀、對稱性和比例。整容手術有多種類型，包括臉部、身體、乳房和活膚。接受整容手術的原因包括增強、矯正和逆轉老化。一個人可以接受整容手術來減少、強調、提升或增強身體特徵。多年來，由於手術技術的改進、富裕程度的提高、都市化的加速、全球化的文化影響以及受過專業培訓的醫生數量的增加，對整容手術的需求顯著增加。

市場促進因素：

  • 由於旨在吸引顧客進行美容護理的許可醫療水療中心的增加，預計該市場將會成長。

接受手術和非手術整容手術的患者數量不斷增加，導致美容醫學行業在世界範圍內不斷發展，並不斷擴大和發展。由於此因素，各國獲得美國批准或許可的醫療食品藥物管理局數量顯著增加。提供多種服務的醫療水療中心的激增帶來了激烈的價格競爭，進一步壓低了美容護理的價格。

  • 技術先進產品的便利性預計將推動全球整容手術的需求。

市場上領先的產品和設備製造商正致力於提高盈利並努力加強其當前的市場佔有率。由於對副作用較小和術後干預的先進產品的需求不斷增加，市場相關人員正在專注於研發以引入先進產品。

按地區

按地區分類，整容手術市場分為北美、南美、歐洲、中東和非洲以及亞太地區。最大的整容手術市場是美國，其次是歐洲。此外，亞太地區預計將擁有最快的市場成長。促成這一成長的因素包括熟練的外科醫生的可用性、醫療保健成本的上升、新興經濟體技術溢出的增加以及外科手術意識的提高。

主要進展

  • 2023 年 2 月，Candela 宣布推出 FDA 核准的 Profound Matrix 系統。該系統旨在糾正、維護和恢復各個衰老階段的皮膚。該系統包括 Sublime、Sublative RF 和 Matrix Pro施用器。 Sublime 和 Sublative RF 可以改善細紋，而 Matrix Pro 可以再生和建構膠原蛋白，從而改善皮膚的整體外觀和紋理。
  • 2022 年 6 月：總部位於倫敦的全球美容公司 Sinclair 宣布重大品牌重塑。該公司在其已經令人印象深刻的注射劑組合中添加了補充藥物，包括 MaiLi 的最新 HA 技術和注射型膠原蛋白刺激劑 Lanluma。新的 EBD 業務描述了各種基於能源的解決方案。辛克萊不斷成長的投資組合、辛克萊學院的教育計畫以及全球影響力反映了其新的身份確認。該品牌已轉型為現代、充滿活力和優質的品牌，同時仍保持其優雅氣質。
  • 2022 年 3 月：矽膠乳房植入製造商 Sientra 20 年來首次獲得加拿大衛生署的核准。 Clarion Medical Technologies 的高強度黏性矽膠乳房植入有臨床資料支持，並具有無與倫比的安全性。 Sienta 是加拿大唯一僅供經過委員會認證的整形外科醫生使用的乳房植入品牌。該公司透過當地合作夥伴 Kai Aesthetic 在加拿大提供植入，確保高品質、安全和服務標準。

提供的產品

  • truSculpt(R) flex：Cutera 的 truSculpt(R) flex 基於原始 MDS（多向刺激），這是一種直接刺激肌肉的全新技術，可提供有保證且可靠的結果。 MDS 採用生物電脈衝，可有效增強、塑形和調理大腿、臀部和腹部。 truSculpt Flex 的腹部、臀部和大腿同時受到八個不同肌肉群的刺激。 truSculpt Flex 比其他塑身設備覆蓋更多的治療空間。運動計畫包括間歇訓練、肌力訓練和體能訓練。 truSculpt 彎曲運動比標準的健身房活動強度更大。
  • Lumenis M22TM模組化美容雷射多用途平台：稱為M22TM的模組化多用途平台用於治療30多種皮膚病和除毛。 M22TM 被世界各地的醫生使用，能夠為各種患者和病症提供有效的治療。 M22TM 可以將四種不同的技術整合到一個模組化系統中。 M22TM 通用 IPL 和 AOPT 的組合為高級用戶提供了完全控制，並允許他們輕鬆地為每個患者和每種情況自訂參數。 Lumenis 還擁有採用 Golden Line 設計的優質 M22 版本，可為美容醫學領域提供準確、安全且非常成功的光和雷射治療。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球整容手術市場：按類型

  • 介紹
  • 手術過程
  • 非手術治療
  • 抽脂手術

第6章全球整容手術市場：依身體區域分類

  • 介紹
  • 臉和胸部
  • 胸部
  • 身體和四肢

第7章全球整容手術市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Candela Corporation
  • Allergan
  • Merz Pharma
  • Mentor Worldwide LLC
  • Lumenis
  • Sinclair Pharma
  • Cutera
簡介目錄
Product Code: KSI061611460

The cosmetic surgery market is anticipated to increase from US$48.24 billion in 2022 to US$89.671 billion in 2029 at a CAGR of 9.26%.

Cosmetic surgery is a type of medical operation that uses both surgical and non-surgical methods to improve looks. Cosmetic surgery, also known as aesthetic surgery, is a branch of plastic surgery that aims to enhance a person's appearance through surgical and medical techniques. It is elective and focuses on improving aesthetic appeal, symmetry, and proportion. There are various types of cosmetic surgery, including facial procedures, body contouring, breast procedures, and skin rejuvenation. Reasons for cosmetic surgery include enhancement, correction, and aging reversal. A person may have cosmetic surgery done to reduce, accentuate, lift, or enhance a physical portion. Over the years, the demand for cosmetic surgery has grown significantly, spurred by improvements in surgical techniques, rising affluence, accelerating urbanization, the cultural effects of globalization, and an increase in doctors with specialized training.

MARKET DRIVERS:

  • An increase in licensed medical spas to draw clientele for cosmetic procedures is anticipated in the growth of the market.

An expansive and appealing aesthetic medicine industry is now operating worldwide because of the rise in the number of patients undergoing surgical and non-surgical cosmetic procedures. The number of medical spas that have FDA approval and licensing has greatly expanded as a result of this factor in many various countries. Intense pricing competition brought on by the proliferation of medical spas offering a wide range of services has driven down the price of cosmetic procedures even more.

  • Technology-advanced product accessibility is expected to drive the demand for cosmetic procedures globally

Leading producers of goods and devices on the market noted the profitable expansion and are working to enhance their current market share. Due to the growing demand for advanced products with fewer side effects and post-surgical interventions, market players are focusing on R&D to introduce advanced products.

By Geography

Geographically, the cosmetic surgery market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The biggest market for cosmetic surgery is in the United States, followed by Europe. Asia Pacific is also anticipated to have the fastest regional market growth. The availability of skilled surgeons, rising healthcare costs, increased technology spillover from developed economies, and expanding awareness of surgery are all factors contributing to this growth.

Key Developments:

  • February 2023: Candela announced the launch of the FDA-cleared Profound Matrix System, designed to correct, maintain, and restore skin at different stages of aging. The system includes the Sublime, Sublative RF, and Matrix Pro applicators. The Sublime and Sublative RF treatments improve fine line and wrinkle appearance, while the Matrix Pro applicator regenerates and builds collagen, enhancing overall skin appearance and texture.
  • June 2022: Sinclair, a London-based global aesthetics company, has announced a significant rebranding. The company has added complementary medicines to its already exceptional range of injectables, including MaiLi's latest HA technology and Lanluma, an injectable collagen stimulant. The new EBD business offers a range of energy-based solutions. Sinclair's growing portfolio, educational programs through Sinclair College, and global presence reflect its new identity. The brand has transformed into contemporary, lively, and premium while maintaining its elegance.
  • March 2022: Sientra, a silicone gel breast implant manufacturer, has been approved by Health Canada for the first time in 20 years. The High-Strength Cohesive Silicone Gel Breast Implants, distributed by Clarion Medical Technologies, are backed by clinical data and have an unrivaled safety profile. Sientra is the only brand of breast implants in Canada available exclusively from board-certified plastic surgeons. The company will offer implants in Canada through local partner Kai Aesthetic, ensuring high quality, safety, and service standards.

Product Offerings:

  • truSculpt(R) flex: Cutera's truSculpt(R) flex is based on the original Multi-Directional Stimulation (MDS), a brand-new technique for direct muscle stimulation that offers secure and reliable outcomes. MDS employs a bioelectrical impulse that has been shown via studies to give targeted muscle stimulation for the best thigh, glute, and abdominal strengthening, firming and toning results. The abdomen, buttocks, and thigh regions of truSculpt flex are simultaneously stimulated by eight different muscle groups. More treatment space is covered by truSculpt flex than by any other body sculpting device. The exercise plans include interval training, strength training, and a conditioning routine. The truSculpt flex workout is much more intense than standard gym-based activities.
  • The Lumenis M22TM Modular Aesthetic Laser Multi-Application Platform: A modular multi-application platform called M22TM is used to treat and remove hair from more than 30 different skin diseases. M22TM, which is used by doctors all over the world, enables one to effectively treat a wide range of patients and conditions. It can combine four different technologies in a Modular System. With the M22TM Universal IPL and AOPT combined, advanced users have complete control and can easily customize the parameters for each patient and each condition. Lumenis also has a premium M22 version with the golden line design that offers the aesthetic medical sector precise, secure, and successful light and laser-based therapies.

Segmentation

By Type

  • Surgical Procedures
  • Non-Surgical Procedures
  • Liposuction

By Body Part

  • Face and Head
  • Breast
  • Body and Extremities

By Geography

  • North America
  • USA
  • Mexico
  • Canada
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • India
  • China
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL COSMETIC SURGERY MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Surgical Procedures
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Non-Surgical Procedures
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Liposuction
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL COSMETIC SURGERY MARKET, BY BODY PART

  • 6.1. Introduction
  • 6.2. Face and Breast
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Breast
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Body and Extremities
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects

Geographic Lucrativeness

7. GLOBAL COSMETIC SURGERY MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Type
    • 7.2.2. By Body Part
    • 7.2.3. By Country
      • 7.2.3.1. United States
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Type
    • 7.3.2. By Body Part
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Type
    • 7.4.2. By Body Part
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. France
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Opportunities and Trends
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Type
    • 7.5.2. By Body Part
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Type
    • 7.6.2. By Body Part
    • 7.6.3. By Country
      • 7.6.3.1. Japan
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. China
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Taiwan
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Thailand
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Candela Corporation
  • 9.2. Allergan
  • 9.3. Merz Pharma
  • 9.4. Mentor Worldwide LLC
  • 9.5. Lumenis
  • 9.6. Sinclair Pharma
  • 9.7. Cutera